Doxorubicin inhibits muscle inflammation after eccentric exercise

Area of Science:

• Oncology
• Exercise Physiology
• Immunology

Background:

• Doxorubicin is a vital anti-cancer drug but causes muscle wasting in patients.
• Understanding doxorubicin's impact on skeletal muscle is crucial for patient care.

Purpose of the Study:

• To investigate doxorubicin's effects on macrophage distribution in exercised skeletal muscle.
• To evaluate the impact of long-term doxorubicin treatment on muscle mass and survival.
• To assess the potential of coenzyme Q10 supplementation to mitigate doxorubicin-induced effects.

Main Methods:

• Rats received acute or long-term doxorubicin injections.
• Soleus muscles were analyzed for macrophage infiltration (M1 and M2) after eccentric exercise.
• Muscle mass, survival rates, and inflammatory markers were assessed.
• Coenzyme Q10 supplementation was administered in some groups.

Main Results:

• Doxorubicin treatment altered inflammatory markers (TNF-alpha, IL-10) in non-exercised muscle.
• Exercise-induced M1 macrophage infiltration and inflammation were reduced in doxorubicin-treated rats.
• Long-term doxorubicin administration led to significant muscle loss and reduced survival.
• Coenzyme Q10 did not reverse muscle loss or improve survival in long-term treatment.

Conclusions:

• Doxorubicin impairs the inflammatory response in exercised skeletal muscle by depleting M1 macrophages.
• Prolonged doxorubicin treatment results in irreversible muscle loss and decreased survival, unaffected by coenzyme Q10.